title: T-DM1 Extends Survival in HER2+ Breast Cancer.
abstract: Results from the phase III TH3RESA study show that T-DM1 is effective in patients with metastatic HER2-positive breast cancer that has progressed despite two or more HER2-targeted therapies, extending their median overall survival by nearly 7 months.
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006801:Humans; D008453:Maytansine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009154:Mutation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D016019:Survival Analysis; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human